title: IgM ocular cicatricial pemphigoid: a unique insight into the immune system.
abstract: A 42-year-old man with ocular erythema and scarring had a conjunctival biopsy revealing depostion of IgM and C3 without IgG at the epithelial basement membrane zone.  Treatment with doxycyline, dapsone, and mycophenolate mofetil was unsuccessful and treatment with rituximab has led to partial remission of the conjunctival inflammation. He has undergone 4 cycles of rituximab treatment at intervals of 12 to 18 months.
authors.affiliation: University of Illinois College of Medicine.
authors.forename: Noor
authors.initials: N
authors.lastname: Tazudeen
authors.forename: Sonoa
authors.initials: S
authors.lastname: Au
authors.forename: Jonathan
authors.initials: J
authors.lastname: Pewitt
authors.forename: Elmer
authors.initials: E
authors.lastname: Tu
authors.forename: Iris K
authors.initials: IK
authors.lastname: Aronson
mesh_terms: D000328:Adult; D000888:Antibodies, Anti-Idiotypic / Q000276:immunology*; D001323:Autoantibodies / Q000276:immunology*; D001706:Biopsy; D003228:Conjunctiva / Q000473:pathology*; D019085:Fluorescent Antibody Technique, Direct / Q000379:methods; D005500:Follow-Up Studies; D006801:Humans; D007113:Immunity, Innate; D007075:Immunoglobulin M / Q000276:immunology*; D007155:Immunologic Factors / Q000627:therapeutic use; D008297:Male; D010390:Pemphigoid, Benign Mucous Membrane / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology*; D012074:Remission Induction; D000069283:Rituximab / Q000627:therapeutic use
chemical_list: D000888:Antibodies, Anti-Idiotypic; D001323:Autoantibodies; D007075:Immunoglobulin M; D007155:Immunologic Factors; D000069283:Rituximab